140 related articles for article (PubMed ID: 31396892)
1. Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis.
Mulubwa M; Mugabo P
Drugs R D; 2019 Sep; 19(3):289-296. PubMed ID: 31396892
[TBL] [Abstract][Full Text] [Related]
2. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.
Mulubwa M; Mugabo P
Br J Clin Pharmacol; 2019 Sep; 85(9):1946-1956. PubMed ID: 31046167
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.
van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491
[TBL] [Abstract][Full Text] [Related]
5. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H
Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.
Court R; Centner CM; Chirehwa M; Wiesner L; Denti P; de Vries N; Harding J; Gumbo T; Maartens G; McIlleron H
Int J Infect Dis; 2021 Apr; 105():688-694. PubMed ID: 33684562
[TBL] [Abstract][Full Text] [Related]
7. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
[TBL] [Abstract][Full Text] [Related]
9. Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.
Alffenaar JWC; Peloquin CA; Migliori GB
Int J Tuberc Lung Dis; 2018 Jan; 22(1):2. PubMed ID: 29297417
[No Abstract] [Full Text] [Related]
10. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.
Hwang TJ; Wares DF; Jafarov A; Jakubowiak W; Nunn P; Keshavjee S
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1257-66. PubMed ID: 23735593
[TBL] [Abstract][Full Text] [Related]
11. [Rezonizat and cycloserine in complex therapy of drug resistant tuberculosis (comparative studies)].
Sokolova GB; Lazareva IaR; Kirtaeva OV; Romanova EV; Tsybane AA
Antibiot Khimioter; 2008; 53(11-12):25-8. PubMed ID: 19441654
[TBL] [Abstract][Full Text] [Related]
12. Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.
Mulubwa M; Mugabo P
Biomed Chromatogr; 2018 Nov; 32(11):e4325. PubMed ID: 29947117
[TBL] [Abstract][Full Text] [Related]
13. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
[TBL] [Abstract][Full Text] [Related]
14. Terizidone.
Vora A
J Assoc Physicians India; 2010 Apr; 58():267-8. PubMed ID: 21046890
[No Abstract] [Full Text] [Related]
15. [Comparative clinical electroencephalographic study of cycloserine and terizidon tolerance].
Shmelev NA; Shabalova LN; Kolosovskaia VP
Antibiotiki; 1975 Feb; 20(2):174-80. PubMed ID: 1091207
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
17. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
Alffenaar JW; Kosterink JG; van Altena R; van der Werf TS; Uges DR; Proost JH
Ther Drug Monit; 2010 Feb; 32(1):97-101. PubMed ID: 20042919
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Mugabo P; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):519-530. PubMed ID: 30617957
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
20. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
